Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vemurafenib [918504-65-1]
Vemurafenib
Catalog No. T2382 CAS 918504-65-1
Synonyms: RO5185426, RG7204, PLX4032
Vemurafenib (RG7204) is a B-RAF inhibitor that inhibits RAFV600E and c-RAF-1 (IC50=31/48 nM) selectively and potently. Vemurafenib exhibits antitumor activity and is used for the treatment of BRAF V600E mutation-positive melanoma.
All TargetMol products are for research or drug registration purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose in violation of laws and regulations.
Vemurafenib, CAS 918504-65-1
| Pack Size | /USD | |
|---|---|---|
| 10 mg | In stock | |
| 50 mg | In stock | |
| 100 mg | In stock | |
| 200 mg | In stock | |
| 500 mg | In stock | |
| 1 mL * 10 mM (in DMSO) | In stock |
Select Batch 
Purity: 99.65%
Purity: 99.65%
Purity: 98.4%
Purity: 98%
Contact us for more batch information
| Description | Vemurafenib (RG7204) is a B-RAF inhibitor that inhibits RAFV600E and c-RAF-1 (IC50=31/48 nM) selectively and potently. Vemurafenib exhibits antitumor activity and is used for the treatment of BRAF V600E mutation-positive melanoma. |
| Targets&IC50 | B-Raf (V600E):31 nM (cell free), Ack1:19 nM (cell free), SRMS:18 nM (cell free), C-Raf1:48 nM (cell free) |
| In vitro | METHODS: Melanoma cells A375 and SK-Mel-28 were treated with Vemurafenib (0-8 μM) for 48 h. Cell viability was detected using CCK-8 assay. RESULTS: Vemurafenib dose-dependently inhibited the proliferation of A375 and SK-Mel-28 cells with IC50 of 0.8 μM and 1.8 μM, respectively.[1] METHODS: Melanoma cell lines Colo829 and LOX expressing BRAF V600E were treated with Vemurafenib (0.05-30 μmol/L) for 2 h, and the expression levels of target proteins were detected by Western Blot. RESULTS: Vemurafenib inhibited the phosphorylation of MEK and ERK in Colo829 and LOX cells. [2] |
| In vivo | METHODS: To assay anti-tumor activity in vivo, Vemurafenib (12.5-75 mg/kg, suspended in an aqueous vehicle containing 2% Klucel LF and adjusted to pH 4 with dilute HCl.) was orally administered to melanoma-carrying Athymic nude mice bearing LOX were administered orally twice daily for 11-13 days. RESULTS: Vemurafenib significantly inhibited tumor growth and induced tumor regression. [2] METHODS: In order to detect the anti-tumor activity in vivo, Vemurafenib (60 mg/kg) was administered orally to athymic mice bearing melanoma Colo-205 twice a day for 14 days. RESULTS: Vemurafenib effectively inhibited tumor growth in the Colo-205 xenograft mouse model. [3] |
| Kinase Assay | Expression and purification of B-RAF, structure determination, and protein kinase activity measurements were carried out as previously described. To obtain co-crystals of B-RAFV600E with PLX4032, the protein solution was initially mixed with the compound dissolved in DMSO at a final compound concentration of 1 mM. This complex was co-crystallized by a sitting drop vapor diffusion experiment in which equal volumes of complex (at 10 mg/ml concentration) and reservoir solution (100mM BisTris at pH 6.0, 12.5% 2,5-hexanediol, and 12% PEG3350) were mixed and allowed to equilibrate against the reservoir at 4°C. The crystal was soaked in cryosolvent, followed by flash-freezing in liquid nitrogen. The data were collected at Beamline ALS831 with the wavelength of 1.11?. The Ramachandran plot from the refined structure shows that 94%, 5.6% and 0.4% residues are in the most favored, additional allowed and generously allowed regions, respectively. A summary of the crystallography statistics is included in Supplementary Table 3. COLO205 tumor xenograft studies (Molecular Imaging Research, Ann Arbor, MI) were carried out as previously described either using a conventional formulation (5%DMSO, 1% methylcellulose) or using the MBP formulation [1]. |
| Cell Research | Cellular proliferation was evaluated by MTT assay. Briefly, cells were plated in 96-well microtiter plates at a density of 1,000 to 5,000 cells per well in a volume of 180 μL. For the assay, RG7204 was prepared at 10 times the final assay concentration in media containing 1% DMSO. Twenty-four hours after cell plating, 20 μL of the appropriate dilution were added to plates in duplicate. The plates were assayed for proliferation 6 days after the cells were plated according to the procedure originally described by Mosmann [2]. |
| Animal Research | All animal procedures were approved by the Ethical Commission of the Institute for Cancer Research and Treatment and by the Italian Ministry of Health. WiDr cells were injected subcutaneously into the right posterior flanks of 7-week-old immunodeficient NODSCID female mice (6 mice per group). Tumour formation was monitored twice a week, and tumour volume based on caliper measurements was calculated by the modified ellipsoidal formula: tumour volume = 1/2 length × width. When tumours reached a volume of approximately 200–250 mm^3, mice were randomly assigned to treatment with vehicle or drug(s) [3]. |
| Synonyms | RO5185426, RG7204, PLX4032 |
| Molecular Weight | 489.92 |
| Formula | C23H18ClF2N3O3S |
| CAS No. | 918504-65-1 |
Storage
Solubility Information
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 18.33 mg/mL (37.42 mM), Sonication is recommended.
References and Literature
1. Liu C, et al. Silencing TCF4 Sensitizes Melanoma Cells to Vemurafenib Through Inhibiting GLUT3-Mediated Glycolysis. Onco Targets Ther. 2020 May 29;13:4905-4915. 2. Yang H, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 2010 Jul 1;70(13):5518-27. 3. Zhang J, et al. EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile. Cancer Biol Ther. 2016;17(2):199-207. 4. Flaherty KT, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010 Aug 26;363(9):809-19.
Citations
1. Cui S, Suo N, Yang Y, et al.The aminosteroid U73122 promotes oligodendrocytes generation and myelin formation.Acta Pharmacologica Sinica.2023: 1-12.
Related compound libraries
This product is contained In the following compound libraries：
Anti-Cancer Clinical Compound Library Anti-Cancer Drug Library FDA-Approved Kinase Inhibitor Library Inhibitor Library EMA Approved Drug Library Drug Repurposing Compound Library Highly Selective Inhibitor Library Anti-Cancer Active Compound Library Kinase Inhibitor Library Tyrosine Kinase Inhibitor Library
Related Products
Related compounds with same targets
Dose Conversion
You can also refer to dose conversion for different animals. More
In vivo Formulation Calculator (Clear solution)
Step One: Enter information below
Dosage
mg/kg Average weight of animals
g Dosing volume per animal
ul Number of animals
Step Two: Enter the in vivo formulation
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL)，
Method for preparing in vivo formulation：Take μL DMSO master liquid, next add μL PEG300， mix and clarify, next add μL Tween 80，mix and clarify, next add μL ddH2O, mix and clarify.
Note:
Be sure to add the solvent(s) in order. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculator
bottom
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Keywords
Vemurafenib 918504-65-1 Angiogenesis Autophagy MAPK Tyrosine Kinase/Adaptors Src ACK Raf Raf kinases PLX 4032 inhibit RG 7204 PLX-4032 Inhibitor RO-5185426 RO5185426 RG7204 RG-7204 RO 5185426 1029872-54-5 PLX4032 inhibitor